Ann: December Quarterly Activities Report, page-5

Agree on the SphygmoCLOUD/Conneqt Band, Sambi.

Our engineering and research teams are making significant progress on our SphygmoCLOUD, CONNEQT Band, and transfer function projects, which will enable seamless integration of our technology into third-party wearables, medical devices, and consumer products. SphygmoCLOUD brings our algorithms to the cloud, simplifying integration with devices such as rings, bands, watches, and other health-focused technologies

Seems to me this is a clear indication of a strategic focus on becoming all-things Cardio Health to all market participants. This will unlock material upfront licensing fees plus, I'd imagine, ongoing royalty streams. Won't happen overnight but when it does, it's a significant development (game-changer?) with the added benefit of raising profile and competitive interest among the big health technology players.

Of note:

We’re also in talks to integrate our systems with the biggest endpoint technology platform in the industry.

Could be wrong, but this is likely to be Clario. If so, it's another major breakthrough catalyst.

ERT and Bioclinica become Clario. PHILADELPHIA – November 3, 2021

ERT, the global clinical trial endpoint technology leader, today announced that following its early Q2 merger with Bioclinica, a technological and scientific leader in medical imaging, the combined company is renamed Clario.

Clario is a technology company that generates the richest clinical evidence by fusing scientific expertise and global scale into the broadest endpoint technology platform. In doing so, Clario empowers its partners to transform lives. Our clinical trial endpoint company is committed to innovating the future of clinical trials through technology and having a positive impact on global healthcare.

With almost 50 years of experience, Clario has mastered generating the reliable evidence needed to bring new medicines, medical devices and therapies to market. Clario’s scientific, regulatory, engineering and operations expertise guides clinical trial partners through every phase of clinical development.

Led by over 200 therapeutic area experts, our clinical trial endpoint company delivers innovative therapeutic area technology solutions to meet clinical trial objectives.

https://clario.com/about/newsroom/ert-and-bioclinica-become-clario/

Also like the Streamlining Operations for Sustainable Growth segment. I like the focus on Sydney, and Australia. Makes it easier to access capital markets as well.

Key changes include centralizing our engineering and development teams in the Sydney office as part of the Company’s 'return to office' policy. This involved transitioning from a predominantly U.S.-based remote workforce, compensated in USD, to a centrally managed team located in Sydney. This move not only aligns with our operational strategy but also delivers substantial management efficiencies and cost savings, particularly given the strength of the USD.
Additionally, we have significantly reduced our reliance on our European-based outsourced engineering contractor by shifting much of that work to Sydney.

There's a lot to like here. Comes down to execution - as it always does - but the language is bullish. You get the impression they've survived a near-death experience, turned the corner and now have a far more technologically robust and financially promising company in the making. There's good money to be made in turnarounds, more so when management are as aligned and committed as Craig, Nial and the rest of the crew.